Barinthus Biotherapeutics (STU:2AB) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.54
GF Value €0.95
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics 3-Year EBITDA Growth Rate?

Barinthus Biotherapeutics STU:2AB 14 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.95. The stock has 1 warning sign investors should review. Among 1,136 Biotechnology companies, Barinthus Biotherapeutics ranks worse than 88028.08% on this metric.

Barinthus Biotherapeutics's EBITDA per Share for the three months ended in Mar. 2026 was €-0.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Barinthus Biotherapeutics was 81.50% per year. The lowest was 8.70% per year. And the median was 45.10% per year.

Barinthus Biotherapeutics  (STU:2AB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Barinthus Biotherapeutics 3-Year EBITDA Growth Rate Related Terms

STU:2AB vs VTGN, PSTV, PVCT: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's 3-Year EBITDA Growth Rate falls into.


STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Barinthus Biotherapeutics (STU:2AB) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Barinthus Biotherapeutics and its competitors. Over the past decade, Barinthus Biotherapeutics' 3-Year EBITDA Growth Rate has ranged from 8.70 to 81.50. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 1136 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' 3-Year EBITDA Growth Rate too high?
Barinthus Biotherapeutics' current 3-Year EBITDA Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 8.70 to a high of 81.50. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 1136 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' 3-Year EBITDA Growth Rate compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Historically, Barinthus Biotherapeutics' own 3-Year EBITDA Growth Rate has ranged from 8.70 to 81.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current 3-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is €0.95, compared to a current price of €0.54 — trading 43.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.54 is trading 43.7% below its estimated GF Value™ of €0.95.

Key valuation signals for STU:2AB:

  • 3-Year EBITDA Growth Rate: 0.00%
  • GF Value™: €0.95 vs. price of €0.54 (43.7% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.54
Price
€0.95
GF Value